Barely Significant
← all excerpts

Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?

Transl Androl Urol · 2012 · PMC4708253 · PMID 26816708

Europe PMCDOI
1
hedged sentence
0.0498
closest p · 1.0× alpha
0.0498
boldest claim

The sentences

only marginally significantP=0.0498actually significant
Finally, out of those who completed the double-blind trial, in the placebo arm 26 patients progressed out of 50 cases while in the tivozanib arm 23 patients progressed out of 58 - the difference between the two cohorts is only marginally significant by a chi-square test (P=0.0498, not reported by the authors).

also in 5,085 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.